Concepedia

Mikhila Mahendra

MM

Statistics

Publications

6

Citations

1.6K

H-Index

6

Active since

2018

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

The University of Texas at Austin

Boehringer Ingelheim (Austria)

Mikhila Mahendra is an author at The University of Texas MD Anderson Cancer Center specializing in molecular oncology, oncology, and medicine.

ORCID

Publications per year

2018–2024

6

Publications

6

An inhibitor of oxidative phosphorylation exploits cancer vulnerability

Jennifer R. Molina, Yuting Sun, Marina Protopopova et al. · Nature Medicine · 2018 · 951 citations · Full text

, , +14

Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

Timothy A. Yap, Naval Daver, Mikhila Mahendra et al. · Nature Medicine · 2023 · 377 citations

, , +14

Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

Christopher P. Vellano, Michael G. White, Miles C. Andrews et al. · Nature · 2022 · 130 citations · Full text

, , +12

Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors.

Timothy A. Yap, Sarina A. Piha‐Paul, Siqing Fu et al. · Journal of Clinical Oncology · 2019 · 70 citations

, , +12

Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance

Venu Thatikonda, Hengyu Lyu, Sabine Jurado et al. · Nature Cancer · 2024 · 47 citations · Full text

, , +14

1–5 of 6